Most important barriers and facilitators of HTA usage in decision-making in Europe.
Kei-Long CheungSilvia M A A EversH De VriesP LevyS PokhrelT JonesM DannerJ WentlandtL KnufinkeS MayerMickaël J C HiligsmannPublished in: Expert review of pharmacoeconomics & outcomes research (2018)
The most paramount barriers and facilitators to HTA usage were quantified. For all countries it is crucial to create an explicit framework for the decision-making context to include HTA evidence. Country differences in the quality of research emphasize the need for enhanced international collaboration in HTA.
Keyphrases